Please login to the form below

Not currently logged in
Email:
Password:

cangrelor

This page shows the latest cangrelor news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

cangrelor. Kengrexal. percutaneous coronary intervention (PCI). P2Y12 inhibitor. The Medicines Company.

Latest news

  • FDA gives the nod to TMC's antiplatelet drug FDA gives the nod to TMC's antiplatelet drug

    Kengreal (cangrelor) has been approved by the FDA for adult patients undergoing percutaneous coronary intervention (PCI) to open a blocked or narrowed coronary artery, three months after being given a green ... TMC's efforts to bring cangrelor to market

  • AZ and Takeda drugs should carry heart failure warning AZ and Takeda drugs should carry heart failure warning

    Cangrelor go-ahead. Meanwhile, the FDA's advisory committee also voted 9 to 2 in favour of approving The Medicines Company's injectable anticoagulant cangrelor as an adjunct to percutaneous coronary ... The FDA is due to deliver a final decision on

  • FDA reviewer backs approval of TMC's cangrelor FDA reviewer backs approval of TMC's cangrelor

    Claims it offers a small benefit over Sanofi’s Plavix.  . The Medicines Company (TMC) looks on course finally to get approval for its intravenous antiplatelet drug cangrelor in the US after ... Analysts had at one point been predicting sales of

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Kengrexal (cangrelor) was recommended for use in the reduction of thrombotic cardiovascular events in adults with coronary artery disease.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics